GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
GlaxoSmithKline PLC (GSK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.141x
Based on the latest financial reports, GlaxoSmithKline PLC (GSK) has a cash flow conversion efficiency ratio of 0.141x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX2.22 Billion) by net assets (GBX15.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GlaxoSmithKline PLC - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how GlaxoSmithKline PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GlaxoSmithKline PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kijcharoen Engineering Electric PCL
BK:KJL
|
0.052x |
|
Eastern Power Group Public Company Limited
BK:EP
|
0.002x |
|
Ikena Oncology Inc
NASDAQ:IKNA
|
-0.030x |
|
Chicago Rivet & Machine Co
NYSE MKT:CVR
|
0.032x |
|
Darya-Varia Laboratoria Tbk
JK:DVLA
|
0.063x |
|
Peloton Minerals Corporation
OTCQB:PMCCF
|
0.185x |
|
Propert & Buil
TA:PTBL
|
0.017x |
|
CATENON SA INH. EO-02
F:8Y9
|
N/A |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC (1991–2024)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC from 1991 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX13.09 Billion | GBX6.55 Billion | 0.501x | -5.32% |
| 2023-12-31 | GBX12.79 Billion | GBX6.77 Billion | 0.529x | -27.86% |
| 2022-12-31 | GBX10.10 Billion | GBX7.40 Billion | 0.733x | +96.80% |
| 2021-12-31 | GBX21.34 Billion | GBX7.95 Billion | 0.373x | -8.15% |
| 2020-12-31 | GBX20.81 Billion | GBX8.44 Billion | 0.406x | -7.15% |
| 2019-12-31 | GBX18.36 Billion | GBX8.02 Billion | 0.437x | -80.95% |
| 2018-12-31 | GBX3.67 Billion | GBX8.42 Billion | 2.293x | +15.66% |
| 2017-12-31 | GBX3.49 Billion | GBX6.92 Billion | 1.983x | +51.46% |
| 2016-12-31 | GBX4.96 Billion | GBX6.50 Billion | 1.309x | +352.40% |
| 2015-12-31 | GBX8.88 Billion | GBX2.57 Billion | 0.289x | -72.41% |
| 2014-12-31 | GBX4.94 Billion | GBX5.18 Billion | 1.049x | +13.43% |
| 2013-12-31 | GBX7.81 Billion | GBX7.22 Billion | 0.924x | +42.57% |
| 2012-12-31 | GBX6.75 Billion | GBX4.38 Billion | 0.648x | -8.42% |
| 2011-12-31 | GBX8.83 Billion | GBX6.25 Billion | 0.708x | +1.52% |
| 2010-12-31 | GBX9.74 Billion | GBX6.80 Billion | 0.697x | -4.45% |
| 2009-12-31 | GBX10.74 Billion | GBX7.84 Billion | 0.730x | -16.95% |
| 2008-12-31 | GBX8.32 Billion | GBX7.31 Billion | 0.879x | +50.31% |
| 2007-12-31 | GBX9.91 Billion | GBX5.79 Billion | 0.585x | +42.54% |
| 2006-12-31 | GBX9.65 Billion | GBX3.96 Billion | 0.410x | -44.42% |
| 2005-12-31 | GBX7.57 Billion | GBX5.59 Billion | 0.738x | -8.08% |
| 2004-12-31 | GBX5.94 Billion | GBX4.77 Billion | 0.803x | -3.95% |
| 2003-12-31 | GBX5.80 Billion | GBX4.85 Billion | 0.836x | +101.83% |
| 2002-12-31 | GBX7.39 Billion | GBX3.06 Billion | 0.414x | -24.54% |
| 2001-12-31 | GBX8.40 Billion | GBX4.61 Billion | 0.549x | +165.41% |
| 2000-12-31 | GBX8.96 Billion | GBX1.85 Billion | 0.207x | +29.48% |
| 1999-12-31 | GBX3.19 Billion | GBX510.00 Million | 0.160x | +7.83% |
| 1998-12-31 | GBX2.77 Billion | GBX410.00 Million | 0.148x | -54.48% |
| 1997-12-31 | GBX1.89 Billion | GBX615.00 Million | 0.325x | -51.44% |
| 1996-12-31 | GBX1.27 Billion | GBX849.00 Million | 0.670x | -88.17% |
| 1995-12-31 | GBX221.00 Million | GBX1.25 Billion | 5.665x | +32.94% |
| 1995-06-30 | GBX574.69 Million | GBX2.45 Billion | 4.261x | +1983.79% |
| 1994-06-30 | GBX5.15 Billion | GBX1.05 Billion | 0.205x | +2.74% |
| 1993-06-30 | GBX4.66 Billion | GBX927.00 Million | 0.199x | +10.25% |
| 1992-06-30 | GBX3.64 Billion | GBX657.00 Million | 0.181x | -3.65% |
| 1991-06-30 | GBX3.28 Billion | GBX615.00 Million | 0.187x | -- |